A humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...

of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda ...

including the start of multiple phase 3 studies of belrestotug in combination with GSK’s PD-1 inhibitor Jemperli (dostarlimab). In GALAXIES, there was a “clinically meaningful” reduction at ...

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

We also have another study involving dostarlimab and niraparib, called FIRST, with a positive press release. It hasn’t been presented at ESGO yet. However, the KEYLYNK-001 trial (GOG 3036) was ...

Myeloproliferative disorders (MPDs) are a group of blood cancers traditionally treated using medications, blood filtration, and chemotherapy or radiation. In recent news, several studies and ...

Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease IPG222 27 June 2007 27 June 2007 Carmustine implants and ...